Modern traditional Chinese Medicine Group: 2022 interim report
National Health Commission: carry out TCM intervention activities in adolescent myopia, obesity and scoliosis
Modern Chinese Medicine Posts Rise in H1 Net Profit
02:59 AM EDT, 08/26/2022 (MT Newswires) -- Modern Chinese Medicine Group (HKG:1643) reported a rise in its consolidated net profit to 49.9 million yuan ($7.3 million) in the six months ended June 30 a
Modern traditional Chinese Medicine Group: interim results announcement for the six months ended June 30, 2022
Modern Chinese Medicine Group (HKG:1643) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Modern Chinese Medicine Group Co., Ltd. (HKG:1643) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details. View our latest
Modern traditional Chinese Medicine Group: annual report 2021
Modern Chinese Medicine's Per-Share Earnings Slip on Higher Expenses in 2021
06:12 AM EDT, 03/25/2022 (MT Newswires) -- Modern Chinese Medicine Group's (HKG:1643) earnings slipped to 0.1377 yuan ($0.022) per diluted share in 2021 from 0.1413 yuan in the previous year, weighed
Modern traditional Chinese Medicine Group: annual results announcement for the year ended December 31, 2021
Modern traditional Chinese Medicine Group: date of board meeting
The concept stock of traditional Chinese medicine rose strongly. Pei Li Nong Ben Fang (01498) rose 5.62%.
Phoenix New Media Hong Kong stock | traditional Chinese medicine concept stock rose strongly. Peili Nong Ben Fang (01498) rose 5.62%, Chinese traditional medicine (00570) rose 5.38%, Tongrentang Technology (01666) rose 2.96%, Modern traditional Chinese Medicine Group (01643) rose 2.47%. Shenwei Pharmaceutical (02877) rose 1.46%. On the face of the news, the State Drug Administration held a forum to promote the comprehensive revitalization of the Northeast. The meeting stressed the need to do a good job in the drug regulatory system to support the comprehensive revitalization of the Northeast. It is necessary to deepen the reform of the examination and approval system, smooth communication channels, speed up the listing of innovative products, and encourage pharmaceutical enterprises.